AlzeCure Pharma
4.11.2021 10:21:53 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 04, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company's latest developments. The presentation will be followed by a Q&A with external experts on-site and Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815899/redeye-life-science-day-2021 . The recorded presentation and the slide set will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Life Science Day 2021 on November 11
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/671149/AlzeCure-Presents-at-Redeye-Life-Science-Day-2021-on-November-11
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Fermi Announces First Siemens Turbines Arrive at Port of Houston21.7.2026 22:30:00 CEST | Press release
Arrival marks an important milestone in the development of Fermi's Project Matador SGT6-5000F natural gas turbines will anchor what is expected to be the nation's largest combined-cycle natural gas project DALLAS, TX / ACCESS Newswire / July 21, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced the arrival of three Siemens Energy SGT6-5000F natural gas turbines at the Port of Houston. Together, the three turbines are rated at up to 780 megawatts in simple-cycle mode. They are bound for Fermi's Project Matador, an advanced energy and AI campus near Amarillo, Texas. This marks one of the project's largest single power-equipment moves, and it keeps Fermi well ahead of competitors in bringing gigawatt-scale power online. The delivery is the latest in a fast run of milestones. Over the past couple of weeks, Fermi selected TSK, Spain's largest power-focused EPC firm, for early works on its phase-two turbines and brought in Prim
GA-ASI and MBDA Commit to Weapons Collaboration21.7.2026 16:00:00 CEST | Press release
Companies Will Integrate SPEAR Onto MQ-9B and Gambit 6 SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and MBDA have announced a commitment to integrate the European missile-maker's SPEAR precision strike weapons onto new aircraft built by the American uncrewed aircraft manufacturer. GA-ASI President David R. Alexander and MBDA UK Managing Director Chris Allam signed a memorandum of understanding that outlined the agreement at the Farnborough International Airshow 2026. The companies will work together to ensure the MQ-9B remotely piloted aircraft and Gambit 6 collaborative combat aircraft (CCA) can carry and use the SPEAR weapons. "We've built an excellent business relationship with MBDA as part of the integration of the Brimstone missile onto the UK's Protector," said Mr. Alexander. "So, working with MBDA to enable SPEAR on our broader MQ-9B line, and our Gambit CCA, feels like a very natural extension of our partnership." Protect
CHAR Tech Welcomes France's Regulatory Advance Opening Biogas Certificate Support to Pyrolysis21.7.2026 14:00:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 21, 2026 / (TSXV:YES)(OTC PINK:CTRNF)(FSE:68K) France proposes opening its flagship renewable gas support scheme (the CPB) to pyrolysis, putting CHAR Tech's HTP technology on the same footing as established production routes in one of Europe's largest gas markets Directly strengthens the HTP project pipeline being developed in France by CHAR Tech's partner GazoTech GazoTech's lead project, Bio-Méthane Provence, is being developed to deploy CHAR Tech's HTP platform to process 115,000 tonnes of recovered wood annually, producing 230 GWh (828,000 GJ) of RNG plus 12,000 tonnes of biocarbon, targeting commercial operations in H2 2029 CHAR Technologies Ltd. ("CHAR Tech" or "the Company"), a leader in sustainable biomass energy solutions, today welcomed a significant regulatory development in France that, if adopted, would open the country's flagship long-term support mechanism for renewable gas to pyrolysis-based production. The development materially str
Fermi Announces Second Quarter 2026 Earnings Release and Call Date20.7.2026 22:30:00 CEST | Press release
Fermi to host earnings call on August 13, 2026 DALLAS, TX / ACCESS Newswire / July 20, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that it plans to release second quarter 2026 financial results at 7 a.m. Eastern Time / 12 p.m. British Time on Thursday, August 13, 2026. This announcement will be followed by an earnings conference call at 9 a.m. Eastern Time / 2 p.m. British Time. The Company's earnings release and supplemental information will be posted to the Investors section of the Company's website prior to the conference call. To join the live conference call, dial 888-506-0062 in the U.S. or +1 973-528-0011 internationally approximately 15 minutes prior to the scheduled start time and refer to conference code 587288. The call will also be webcast in a listen-only mode and can be accessed through the Investor Relations Events & Presentations page of Fermi's website. A replay of the webcast will be available for
GA-ASI and KONGSBERG Advance JSM Integration for MQ-9B20.7.2026 12:05:00 CEST | Press release
Companies Bring Joint Strike Missile Weapon System to Leading Uncrewed Platform SAN DIEGO, CA / ACCESS Newswire / July 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and KONGSBERG Gruppen ASA (KONGSBERG) completed the System Requirements Review (SRR) and Preliminary Design Review (PDR) for the integration of the Joint Strike Missile (JSM) weapon system onto MQ-9B. This design and integration effort is a jointly funded project by both companies aimed at providing long-range strike capability for MQ-9B and its customers. These reviews were successfully completed in Kongsberg, Norway, on June 30. MQ-9B is an industry-leading uncrewed aircraft system (UAS) manufactured by GA-ASI and includes the SkyGuardian® and SeaGuardian® models. KONGSBERG produces the JSM, a best-in-class weapon system for use against high-priority targets. "We recognize the value JSM brings to our MQ-9B platform," said Niki Johnson, GA-ASI Vice President, International Capture and Government Affairs. "
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom